---
document_datetime: 2025-12-09 10:15:52
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aubagio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aubagio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9825532
conversion_datetime: 2025-12-30 20:18:23.003007
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## AUBAGIO

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 06/11/2025                          |                                             | SmPC and PL                      | Section 4.4 is updated to add a warning on skin |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000292811                        | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.4 of the SmPC in order to add a new warning on skin reactions based on literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.                                                                                                                                                                                                       |            |     | reactions: Skin ulcers and impaired wound healing may potentially occur in patients during therapy with AUBAGIO. If AUBAGIO-associated skin ulcer is suspected, if skin ulcers persist despite appropriate therapy, or if there is a high risk for impaired wound healing after surgery, consider AUBAGIO discontinuation and an accelerated drug elimination procedure. The decision to resume AUBAGIO should be based on clinical judgment of adequate wound healing. For more information, please refer to the Summary of Product Characteristics.   |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000302244 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active | 09/10/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                                       | (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000269779 | This was an application for a group of variations. B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member                                                                                                                                                                                                                                                                                                                                                           | 16/05/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted B.I.b.2 Change in test procedure for active substance or starting   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Refused A. ADMINISTRATIVE CHANGES - A.4 Change   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Refused                                                                                                                                                                                                              |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000253990 | This was an application for a group of variations. B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Refused B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Refused B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an | 13/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Eur. or national pharmacopoeia of a Member  State - Refused  B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Refused  B.III.2 Change to comply with Ph. Eur. or  with a national pharmacopoeia of a Member  State - B.III.2.b Change to comply with an  update of the relevant monograph of the Ph.  Eur. or national pharmacopoeia of a Member  State - Refused  B.III.2 Change to comply with Ph. Eur. or  with a national pharmacopoeia of a Member  State - B.III.2.b Change to comply with an  update of the relevant monograph of the Ph.  Eur. or national pharmacopoeia of a Member  State - Refused  B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Refused  B.III.2 Change to comply with Ph. Eur. or   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Refused B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Refused A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Refused A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance,   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Refused A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Refused B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Refused   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|